pharmaceutical investing Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
ReeXploration Announces Field Program Results Confirming Large-Scale Uranium Target at Eureka, Namibia
